44 results about "Skeletal muscle" patented technology

This invention relates to the application of oridonin in the preparation of agents that improve muscle function, specifically by improving skeletal muscle dysfunction, enhancing insulin sensitivity, promoting myoblast differentiation into myotube cells, and / or increasing myoblast insulin sensitivity. Using an in vitro C2C12 myoblast model, this invention demonstrates that oridonin can promote myoblast differentiation and growth and increase C2C12 myoblast insulin sensitivity. Through an obesity-induced skeletal muscle dysfunction model, it is demonstrated that oridonin can improve skeletal muscle dysfunction and insulin resistance by increasing muscle strength, muscle endurance, muscle mass, and reducing muscle lipid accumulation. This invention provides new insights for drug research on improving skeletal muscle dysfunction and enhancing insulin sensitivity, and also enriches the pharmacological system of oridonin.

The application belongs to the field of food processing and biomedical technology, and discloses a preparation method of a salty taste enhancing peptide-naringenin compound and application of the compound in improving cognitive decline. The compound is prepared by compounding salty taste enhancing peptides from soft-shelled turtle eggs and naringenin at a ratio of 20-150:1 (w:w). The preparation process comprises the following steps: soft-shelled turtle egg enzymolysis, ultrafiltration, freeze-drying to obtain salty taste enhancing peptides, mixing the salty taste enhancing peptides with a naringenin solution, concentration, and freeze-drying. The compound has good stability, salty taste enhancing and antioxidant activities, can reduce the use of salt and maintain salty taste. The compound can improve cognitive decline and anxiety caused by aging and diabetes, improve autonomous activity, memory and social skills, strengthen physical fitness, protect nerve cells and skeletal muscles, maintain brain tissue health, and can be applied to the preparation of related preparations for improving cognitive decline.

The present application relates to the technical field of livestock feed, and particularly relates to a feed for improving muscle growth of broilers and application of a molecular marker (His-Thr-Gln-Glu) of the feed in cells, and provides a molecular marker for regulating animal skeletal muscle, and an amino acid sequence of the molecular marker is His-Thr-Gln-Glu, and the molecular marker can be applied to preparation of a product for regulating animal skeletal muscle as a target.

The present invention relates to the effect of promoting muscle development and growth through inhibition of the expression of MRF4. According to the present invention, MRF4 isolated and identified from skeletal muscles of Nile tilapia showed a strong association with MyoG and MEF2 proteins, and the expression of MyoG and MEF2 was found to significantly increase when the MRF4 gene was disrupted through CRISPR / Cas9 gene editing, and thus the present invention has the effect of being able to be used for the promotion of muscle development or the treatment of muscle diseases through the inhibition of the MRF4 gene.

The present invention relates to methods of improving muscle function in a subject suffering from a disease or condition in which muscle function is impaired, the method comprising administering an effective amount of, an inhibitor of FGFR3 signaling, an NPR-B agonist or an NPR-C agonist to said subject.

The present disclosure relates to the fields of molecular biology and nucleic acid technology. The present disclosure also relates to the therapy and prevention of disease.

This invention discloses the application of a UBC9 overexpression reagent in the preparation of drugs for preventing hypothermia caused by acute cold exposure, belonging to the field of biomedical technology. In vitro and in vivo experiments confirmed that acute cold exposure can induce a significant upregulation of UBC9 expression in skeletal muscle. Further, a skeletal muscle-specific UBC9 overexpression mouse model was constructed, revealing that UBC9 overexpression significantly enhances the core body temperature maintenance capacity of mice under acute cold exposure, upregulates the expression of the key thermogenic protein UCP3 and mitochondrial functional proteins TOMM20 and COX4, alleviates mitochondrial structural damage, and reduces mitochondrial oxidative stress levels. This invention reveals for the first time that UBC9 is a key target for the regulation of skeletal muscle thermogenicity under acute cold exposure. Enhancing UBC9 expression can effectively prevent or improve skeletal muscle thermogenic dysfunction caused by cold environments, providing a novel intervention strategy for developing drugs to prevent and treat cold injury.

This application provides a heterocyclic compound, a pharmaceutical composition, an activin type II receptor inhibitor, and their applications. The heterocyclic compound is a compound of Formula I or its racemic, stereoisomer, geometric isomer, tautomer, nitride, hydrate, isotope label, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, or pharmaceutically acceptable prodrug. This heterocyclic compound, pharmaceutical composition, and activin type II receptor inhibitor can effectively inhibit activin receptor 2B with high selectivity, showing promising application prospects in the preparation of anti-cachexia drugs, anti-muscle muscular atrophy drugs, or anti-metabolic disease drugs.

The application relates to application of miRNA and / or a miRNA agonist in preparation of a medicine for preventing and / or treating myocardial ischemia-reperfusion injury, and belongs to the technical field of biological medicine. The medicine is administered through skeletal muscle injection, is secreted to a circulation system after expression on the skeletal muscle, is delivered to heart tissue by taking extracellular vesicles as carriers, and thus regulates myocardial cell functions. According to the animal model verification result, the miRNA can be delivered to the heart by the extracellular vesicles secreted by the skeletal muscle through injection of the medicine into the skeletal muscle, the expression level of the miRNA in the I / RI heart is significantly increased, the myocardial infarction area is effectively reduced, myocardial cell apoptosis is inhibited, myocardial fibrosis is reduced, and heart function is improved, a brand-new intervention strategy is provided for treatment of myocardial ischemia-reperfusion injury and related heart diseases, and a brand-new idea is opened up for research and development of heart failure treatment medicines.

The application discloses CircSESN1 a gene, an overexpression vector thereof, a specific primer pair, a detection kit and application thereof. CircSESN1 The application also discloses application of the gene, the overexpression vector, the specific primer pair or the fluorescent quantitative detection kit in regulation of chicken skeletal muscle growth and development. CircSESN1 The application further discloses a method for inhibiting proliferation and / or promoting differentiation of chicken myoblasts. The detection kit provided by the application can be used for detecting

Disclosed in the present invention are 7-azaindole compounds, a preparation method therefor, and the use thereof, belonging to the field of drug synthesis. The present invention particularly relates to 7-azaindole compounds containing pyrazole or indole substitution represented by general formula (I), a preparation method therefor and the use thereof in medicine. The compounds of the present invention alleviate cancer cachexia skeletal muscle atrophy by means of inhibiting ActRIIB protein in the MSTN pathway, thereby achieving a remarkable anti-cancer-cachexia effect. Experimental results show that the compounds have good anti-cachexia activity and thus can be further used for preparing novel anti-cachexia drugs.

The application discloses application of papyriquinone in treatment of muscular dystrophy. The inventors find that papyriquinone can be combined with ERRa, activate ERRa and downstream signal pathways, promote muscle cell differentiation, improve muscle function, promote skeletal muscle regeneration, and finally plays a therapeutic role on Duchenne muscular dystrophy.

The application discloses an antibody for detecting cardiovascular diseases and application thereof, and belongs to the technical field of biological medicine. The monoclonal antibody or antigen binding fragment thereof provided by the application can specifically bind to a specific antigen epitope (SEQ ID NO:1) of human cardiac troponin I (cTnI) and has no cross reaction with skeletal muscle troponin I. The application further discloses the CDR sequences of the heavy chain and light chain variable regions of the antibody, a coding gene, a preparation method and application thereof. An ELISA detection kit containing the antibody can specifically recognize cTnI in a blood sample, has good linearity in the range of 0.01-50 ng / mL, has a false negative rate of 0 for serum detection of patients with acute myocardial infarction, and has a low false positive rate for serum detection of healthy people. The antibody and the kit have important application value in rapid and accurate diagnosis of cardiovascular diseases such as acute myocardial infarction.

This invention belongs to the field of small molecule pharmaceutical compounds and relates to the application of trimetazidine in the preparation of drugs for treating glycogen storage diseases. This invention provides a novel treatment strategy for glycogen storage diseases, discovering that the small molecule compound trimetazidine can reduce the load on lysosomal pathways, further reducing cellular glycogen accumulation, thus achieving a therapeutic effect on glycogen storage diseases. In animal experiments, observations of skeletal muscle movement in mice confirmed that trimetazidine significantly enhances muscle function and strength in mice with glycogen storage diseases. Therefore, trimetazidine can be used clinically for the prevention or treatment of glycogen storage diseases, and possesses the advantages of small molecular weight, oral administration, and low cost for industrialization.

The invention relates to a viral expression construct and related viral vector and nucleic acid molecule and composition and to their use wherein said construct and vector are suitable for expression in a mammal and comprise a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) to be expressed in liver, adipose tissue and / or skeletal muscle.

The present invention is related to a composition comprising a novel chemical compound with the chemical Name "4-(4-((4-Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2- isopropylphenol" and its use. The 4-(4-((4-Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2- isopropylphenol and related compounds are useful for treating microgravity induced damage such as skeletal muscle atrophy and dysfunction as well as cardiac dysfunction and are also useful for human diseases and conditions accompanied by significant loss of muscle mass and reduced endurance capacity, such as immobilized patients, cancer, heart failure, sepsis, diabetes mellitus, muscle genetic diseases and neurodegenerative disorders. In addition, 4-(4-((4- Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2-isopropylphenol and related compounds are useful for treating human diseases related to muscle degeneration and ageing such as sarcopenia and heart failure.

This invention discloses a functional analysis system for skeletal muscle organoids and its applications. The core of the system lies in its use of computer vision technology to automatically analyze motion videos of calcium-ion fluorescently labeled skeletal muscle organoids under stimulation. The system automatically identifies organoid regions of interest (ROIs) through specific image processing algorithms (such as adaptive threshold fusion and contour detection), extracts time-series data of calcium signal intensity, and calculates characteristic parameters such as relative fluorescence change rate and peak frequency, ultimately outputting a quantitative functional assessment report. This assessment scheme is low-cost, high-throughput, objective, and accurate, overcoming the technical bottleneck of existing organoid functional assessments that rely on subjective manual analysis or expensive specialized equipment. It is compatible with various culture systems, greatly promoting the large-scale application of skeletal muscle organoids in drug screening and toxicity testing.

The present application relates to the technical field of motion trajectory tracking, in particular to a skeletal muscle motion trajectory tracking system for early screening of myasthenia gravis patients. The system comprises: acquiring position coordinates and motion trajectories of key skeletal muscle nodes; determining the abnormal degree of muscle strength efficiency according to the instantaneous motion state fluctuation and curvature distribution of the motion trajectories; acquiring the bending angle and time sequence electrical signals of the target muscle pair of the muscle with synergistic effect, and determining the degree of synergy breakdown according to the fluctuation correlation of the time sequence electrical signals and the bending angles of different muscles; combining the abnormal degree of muscle strength efficiency and the degree of synergy breakdown to determine the motion trajectory abnormality coefficient, and tracking and screening based on the motion trajectory abnormality coefficient. The present application can effectively capture the irregular transition characteristics from "steady state to tremor state" of intermittent myasthenia, and effectively improve the sensitivity of early myasthenia screening.

This invention proposes a CT medical image processing and recognition method and system for sarcopenia. The method includes: acquiring CT images and performing image preprocessing; establishing a task-driven closed-loop fitness function based on sarcopenia pathological image feature enhancement parameters, and using an adaptive particle swarm optimization algorithm to enhance sarcopenia pathological features; using a multi-scale adaptive Gaussian filter combination to enhance the edges of the adaptively enhanced image, and using a segmentation model for pixel-level segmentation to identify and locate the image regions corresponding to skeletal muscle, subcutaneous fat, and visceral fat. This invention combines traditional particle swarm optimization with an adaptive optimization strategy targeting sarcopenia features. It can automatically adjust the enhancement strategy according to image contrast and noise level, and with multi-scale adaptive Gaussian filtering, intelligently enhance muscle edges according to tissue density, clearly distinguishing skeletal muscle from fat and viscera, and improving the problem of inconsistent image quality under different original image acquisition conditions.

The present application relates to the technical field of immunology and meat product adulteration meat source identification, and provides a hybridoma cell strain, an anti-fox skeletal muscle troponin monoclonal antibody produced by the hybridoma cell strain and application of the antibody, the preservation name of the hybridoma cell strain is: the hybridoma cell strain skTn-3A4 of the anti-fox skeletal muscle troponin monoclonal antibody, the preservation place is China Center for Type Culture Collection, the preservation date is October 10, 2023, and the preservation number is CCTCC NO: C2023302.The anti-fox skeletal muscle troponin monoclonal antibody skTn-3A4 provided by the present application can be used for preparing an enzyme-linked immunoassay kit, a colloidal gold chromatography test strip and an evanescent wave fluorescence immune sensor for detecting fox skeletal muscle troponin, so that the fox skeletal muscle troponin in food can be rapidly and sensitively detected.

This invention relates to the field of edge computing technology for medical monitoring, specifically to an orthopedic rehabilitation monitoring network system and method based on edge intelligent decision-making technology. The method discloses an orthopedic rehabilitation monitoring network method based on edge intelligent decision-making technology. This method acquires standardized multimodal sensory data from patients, and a local edge computing node calls a built-in lightweight skeletal muscle biomechanical model for real-time calculation, extracting joint range of motion, electromyographic envelope, and gait spatiotemporal parameters. These parameters are then input locally into a pre-trained posture anomaly detection decision tree for frame-by-frame comparison and analysis. When any parameter deviates from a preset standard, a posture anomaly event label and associated sensor data slice are immediately generated locally. This lightweight alarm information is transmitted to a regional rehabilitation monitoring center server, triggering the retrieval of high-definition images. This method achieves local real-time intelligent detection and early warning of rehabilitation anomalies, reducing network load and response latency.

The application is suitable for the technical field of intelligent algorithm, and provides a sarcopenia rehabilitation strategy generation method and related equipment, including: acquiring four-limb skeletal muscle data, whole-body muscle density data and bone density value data of a target user, and acquiring muscle function data of the target user according to a user type of the target user and according to a preset rule; performing profiling on the target user by a preset diagnosis algorithm based on the four-limb skeletal muscle data, the whole-body muscle density data and the muscle function data, to obtain a profiling result; and selecting a rehabilitation strategy for the target user in a preset database according to the user type, the profiling result and the bone density value data.

The application belongs to the technical field of medicine, and particularly relates to a blood vessel targeting anti-aging oral composition and application thereof. In view of problems such as endothelial dysfunction, matrix sclerosis and accumulation of senescent cells caused by vascular aging, the composition comprises active ingredients: beetroot extract, fisetin, salvianolic acid B, panax notoginseng total saponins, cocoa flavanol, pterostilbene, procyanidin B2, luteolin, nicotinamide riboside and astaxanthin. The composition is prepared by a process of adsorbing astaxanthin on beetroot extract, mixing other active ingredients, fillers and glidants after fisetin and salvianolic acid B are prepared into a solid dispersion, and sequentially cooperating each module, so that the pulse wave transmission velocity can be significantly reduced and the skeletal muscle capillary density can be increased, and the composition is mainly used for preparing a medicine for improving vascular stiffness, promoting microcirculation and removing vascular senescent cells.

The application belongs to the technical field of biological medicine, and discloses a compound preparation for invigorating the spleen, regulating qi and removing blood stasis and application thereof in preparation of a medicine for improving gastrointestinal function disorder caused by chemotherapy. The compound preparation is composed of radix pseudostellariae, fried atractylodes, poria cocos, fried liquorice, fried pinellia, dried tangerine or orange peel, fried coix seed, fried rice sprout, fried wheat germ, fried chicken gizzard, inula flower, fig, root of actinidia, root of syzygium buxifolium, and turmeric. The scheme improves and develops the theory system of combination of traditional Chinese medicine and western medicine in colorectal cancer, and is applied in clinic. The whole prescription has the effects of invigorating the spleen, regulating qi, removing blood stasis, and resisting cancer, and the compatibility of the medicines shows a significant synergistic effect. The comprehensive curative effect is better than that of single type of medicine or simple combination, especially in improving the nutritional metabolism index and maintaining the skeletal muscle mass, and the prescription has unique advantages, thereby improving the immune function of the body, effectively improving the life quality of patients, and improving the chemotherapy tolerance.

A topical cream or ointment is provided that provides for the binding to CB1 and / or CB2 receptors for the soothing of pain, inflammation of smooth muscle, tendons, ligaments, skeletal muscle, endothelial cell, synovial cell, peripheral nerve fibers, reduction of endothelial bruising, promotion of healing of endothelial bruising, and dermatological itch sensation wherein the improvement comprises providing the effect of cannabinoid using plant extracts. A topically administered formulation is also provided for treating anal mucosal inflammation, soothing of pain, inflammation of anal mucosal inflammation; reducing keratinocyte apoptosis; treating viral-associated epithelial damage, treating radiation dermatitis; and treating chemotherapy-induced dermatitis.

An electroporation ablation system for treating a target tissue in a patient. The electroporation ablation system includes an ablation catheter and an electroporation generator. The ablation catheter includes a handle, a shaft having a distal end, and a catheter electrode at the distal end of the shaft and spatially arranged to generate an electric field in the target tissue in response to an electric pulse. The electroporation generator is operably coupled to the catheter electrode and configured to deliver an electric pulse in a sequence of irreversible electroporation pulses to the one or more catheter electrodes, the sequence of irreversible electroporation pulses including a pre-treatment pulse sequence and an electroporation pulse sequence. Wherein the pre-treatment pulse sequence includes pre-treatment electric pulses configured to cause electrolysis in the vicinity of the target tissue and to cause skeletal muscle stimulation tetanus in the patient.

Suppression of HIPPO signaling in the stem cell niche promotes skeletal muscle regeneration [Solution] Embodiments of the present disclosure include methods for generating skeletal muscle by targeting the HIPPO pathway. In certain embodiments, an individual with a need for skeletal muscle generation is provided with an effective amount of an shRNA molecule that targets the SAV1 gene. Specific shRNA sequences are disclosed.